Xigen SA   Report issue

For profit Phase 2 Phase 3
Founded: Epalinges Switzerland (2002)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2011
NCT01570205
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

hyaluronic acid (3 trials)

Drugs in Phase 2 Trials (1)

xg-104 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Dry Eye Syndromes (Phase 2)

Inflammation (Phase 3)

Keratoconjunctivitis Sicca (Phase 2)

Uveitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2